Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Diabetic Complications: Diagnosis, Treatment, and Management
jcm-logo
Submit to JCM Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Diabetic Complications: Diagnosis, Treatment, and Management

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Endocrinology & Metabolism".

Deadline for manuscript submissions: closed (31 August 2024) | Viewed by 2809

Special Issue Editor

Dr. Pasquale Mone

E-Mail Website
Guest Editor
1. Department of Mental and Physical Health and Preventive Medicine, University of Campania Luigi Vanvitelli, 81100 Naples, Italy
2. ASL Avellino, 83100 Avellino, Italy
3. Casa di Cura Montevergine, 83013 Mercogliano, AV, Italy
Interests: older adults; diabetes; hypertension; heart failure; cognitive impairment; physical impairment
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Diabetes mellitus (DM) is one of the most common determinants of cardiovascular disease and complications, increasing the risk of heart failure (HF). DM drives a shift in cardiac metabolism targeting adrenergic signaling, cardiac fibroblasts, cardiomyocytes, endothelial cells, and vascular smooth cells. Indeed, hyperglycemia and insulin resistance are detrimental to the determination of inflammation, oxidative stress, atherosclerosis, and cardiovascular dysfunction. Hence, the present Special Issue aims to summarize the main mechanisms of diabetic cardiomyopathy and HF, focusing on the diagnosis and management of these patients. Both preclinical and clinical manuscripts are welcome.

Dr. Pasquale Mone
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • diabetes
  • insulin resistance
  • hyperglycemia
  • oral antidiabetic drugs
  • diabetic cardiomyopathy
  • heart failure
  • SGLT2 inhibitors
  • cardiac metabolism
  • adrenergic signaling
  • oxidative stress
  • inflammation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

13 pages, 1979 KiB  
Article
Identification of Adipsin as a Biomarker of Beta Cell Function in Patients with Type 2 Diabetes
by Jae-Hyung Park, Thi Nhi Nguyen, Hye Min Shim, Gyeong Im Yu, Eun Yeong Ha and Hochan Cho
J. Clin. Med. 2024, 13(23), 7351; https://doi.org/10.3390/jcm13237351 - 2 Dec 2024
Viewed by 902
Abstract
Background/Objectives: Adipsin, an adipokine, is known to play an important role in maintaining the function of pancreatic beta cells in mice. This study aimed to investigate whether adipsin could be a circulating biomarker for evaluating the function of beta cells in patients [...] Read more.
Background/Objectives: Adipsin, an adipokine, is known to play an important role in maintaining the function of pancreatic beta cells in mice. This study aimed to investigate whether adipsin could be a circulating biomarker for evaluating the function of beta cells in patients with type 2 diabetes (T2D). Methods: Plasma adipsin concentrations were measured using immunoassay in three distinct subject groups: normoglycemia, T2D without insulin treatment (T2D-w/o-insulin), and T2D treated with insulin (T2D-with-insulin). Adipsin expressions were evaluated in three distinct mouse groups: normal diet (ND), high-fat diet (HFD), and HFD with streptozotocin (STZ) and nicotinamide (NA). Results: The T2D-with-insulin group exhibited a significant decrease in plasma adipsin concentration (3.91 ± 1.51 μg/mL) compared to the T2D-w/o-insulin group (5.11 ± 1.53 μg/mL; p < 0.001), whereas the T2D-w/o-insulin group showed a significantly increased plasma adipsin concentration compared to the normoglycemia group (4.53 ± 1.15 μg/mL). Plasma adipsin concentration was positively correlated with fasting C-peptide level (p < 0.001), 2-h C-peptide level (p < 0.001), and 2-h C-peptidogenic index (p < 0.001) in the diabetic groups. HFD mice showed a significant increase in pancreatic islet size, plasma insulin and adipsin levels, as well as adipsin expression in white adipose tissue (WAT) compared to ND mice. In contrast, the insulin-deficient T2D model (HFD-STZ-NA) demonstrated a marked reduction in pancreatic islet size, plasma insulin and adipsin concentrations, and adipsin expression in WAT compared to the HFD mice. Conclusions: plasma adipsin may be useful for evaluating pancreatic beta cell function in patients with T2D. Full article
(This article belongs to the Special Issue Diabetic Complications: Diagnosis, Treatment, and Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

18 pages, 985 KiB  
Review
The Role of Stress Hyperglycemia on Delirium Onset
by Ester Lagonigro, Antonella Pansini, Pasquale Mone, Germano Guerra, Klara Komici and Carlo Fantini
J. Clin. Med. 2025, 14(2), 407; https://doi.org/10.3390/jcm14020407 - 10 Jan 2025
Viewed by 1158
Abstract
Delirium is an acute neuropsychiatric syndrome that recognizes one or more underlying causal medical conditions. Stress hyperglycemia usually refers to transient hyperglycemia associated with stress conditions such as stroke, myocardial infarction, and major surgery. Both delirium and stress hyperglycemia share common pathways, such [...] Read more.
Delirium is an acute neuropsychiatric syndrome that recognizes one or more underlying causal medical conditions. Stress hyperglycemia usually refers to transient hyperglycemia associated with stress conditions such as stroke, myocardial infarction, and major surgery. Both delirium and stress hyperglycemia share common pathways, such as activation of inflammation. Stress hyperglycemia has been associated with negative outcomes, and recent studies suggested that there is an increased risk of delirium onset in patients with stress hyperglycemia. The purpose of this review is to illustrate the relationship between stress hyperglycemia and delirium. Initially, we illustrate the role of diabetes on delirium onset, summarize the criteria used for the diagnosis of stress hyperglycemia, discuss the impact of stress hyperglycemia on outcome, and focus on the evidence about the relationship between stress hyperglycemia and delirium. Full article
(This article belongs to the Special Issue Diabetic Complications: Diagnosis, Treatment, and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop